Antimicrobial and immunosuppressive drug interactions in solid organ transplant recipients

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 30, Issue SUPPL.2, 2012, Pages 86-92

  Berdaguer, Soledad ^a   Bautista, Javier ^a   Brunet, Mercè ^b   Cisneros, José Miguel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Antibacterials; Antifungals; Antimicrobials; Antiretrovirals; Antivirals; Drug interaction; Immunosuppressants; Transplantation

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; METHYLPREDNISOLONE; METRONIDAZOLE; MYCOPHENOLIC ACID; NAFCILLIN; NORFLOXACIN; POSACONAZOLE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STEROID; TACROLIMUS; TELITHROMYCIN; TROLEANDOMYCIN; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ACUTE GRAFT REJECTION; ADRENAL INSUFFICIENCY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; HUMAN; INTESTINE FLORA; KIDNEY FUNCTION; LIVER CIRCULATION; LIVER METABOLISM; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NEPHROTOXICITY; ORGAN TRANSPLANTATION; UNSPECIFIED SIDE EFFECT;

ANTI-INFECTIVE AGENTS; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 84860458762     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(12)70087-3     Document Type: Article

References (34)

1. A. Termeer, A.J. Hoitsma, and R.A. Koene Severe nephrotoxicity caused by the combined use of gentamicin and ciclosporine in renal allograft recipients Transplantation 42 1986 220 221
2. J.M. Hows, P.M. Chipping, S. Fairhead, J. Smith, A. Baughan, and E.C. Gordon-Smith Nephrotoxicity in bone marrow transplant recipients treated with ciclosporine A Br J Haematol 54 1983 69 78
3. Novartis Spain. Sanndimmun neoral (ciclosporin microemulsion). Spanish summary of product characteristics. June 2011.
4. F. Jahansouz, J.M. Kriett, C.M. Smith, and S.W. Jamieson Potentiation of ciclosporin nephrotoxicity by nafcillin in lung transplant recipients Transplantation 55 1993 1045 1048
5. R. Borrows, G. Chusney, M. Loucaidou, A. James, J. Van Tromp, and T. Cairns The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil based renal transplantation Ther Drug Monit 29 2007 122 126
6. B. Sádaba, A. López de Ocáriz, J.R. Azanza, J. Quiroga, and J.A. Cienfuegos Concurrent clarithromycin and ciclosporin A treatment J Antimicrob Chemother 42 1998 393 395
7. J.D. Harnett, P.S. Parfrey, M.D. Paul, and M.H. Gault Erythromycin-ciclosporine interaction in renal transplant patients Transplantation 43 1987 316 318
8. P.W. Kunicki, and M. Sobieszczanska-Malek Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient Ther Drug Monit 27 2005 107 108
9. C. Jensen, M. Jordan, R. Shapiro, V. Scantlebury, T. Hakala, and J. Fung Interaction between tacrolimus and erythromycin Lancet 344 1994 825
10. D. Capone, G. Palmiero, A. Gentile, V. Basile, S. Federico, and M. Sabbatini A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient Curr Drug Metab 8 2007 379 381
11. K. Claesson, C. Brattström, and J.T. Burke Sirolimus and erythromycin interaction: Two cases Transplant Proc 33 2001 2136
12. Rapamune. Available at: Http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000273/WC500046437.pdf
13. J.M. Kovarik, D. Beyer, M.N. Bizot, Q. Jiang, M. Shenouda, and R.L. Schmouder Effect of multiple-dose erythromycin on everolimus pharmacokinetics Eur J Clin Pharmacol 61 2005 35 38
14. D.A. Fost, D.Y. Leung, R.J. Martin, E.E. Brown, S.J. Szefler, and J.D. Spahn Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy J Allergy Clin Immunol 103 1999 1031 1035
15. C.F. LaForce, S.J. Szefler, M.F. Miller, W. Ebling, and M. Brenner Inhibition of methylprednisolone elimination in the presence of erythromycin therapy J Allergy Clin Immunol 72 1983 34 39
16. S.J. Szefler, J.Q. Rose, E.F. Ellis, S.L. Spector, A.W. Green, and W.J. Jusko The effect of troleandomycin on methylprednisolone elimination J Allergy Clin Immunol 66 1980 447 451
17. O.J. Naderer, R.E. Dupuis, E.L. Heinzen, K. Wiwattanawongsa, M.W. Johnson, and P.C. Smith The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil J Clin Pharmacol 45 2005 219 226
18. A.E. El-Agroudy, A.F. Refaie, O.M. Moussa, and M.A. Ghoneim Tuberculosis in Egyptian kidney transplant recipients: Study of clinical course and outcome J Nephrol 16 2003 404 411
19. M.F. Hebert, R.M. Fisher, C.L. Marsh, D. Dressler, and I. Bekersky Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers J Clin Pharmacol 39 1999 91 96
20. M. Naesens, D.R. Kuypers, F. Streit, V.W. Armstrong, M. Oellerich, and K. Verbeke Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients Clin Pharmacol Ther 80 2006 509 521
21. J.M. Kovarik, S. Hartmann, J. Figueiredo, M. Rouilly, A. Port, and C. Rordorf Effect of rifampicin on apparent clearance of everolimus Ann Pharmacother 36 2002 981 985
22. Everolimus. Available at: Http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/001038/WC500022814.pdf
23. V. Kyriazopoulou, O. Parparousi, and A.G. Vagenakis Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy J Clin Endocrinol Metab 59 1984 1204 1206
24. W.A. McAllister, P.J. Thompson, S.M. Al-Habet, and H.J. Rogers Rifampicin reduces effectiveness and bioavailability of prednisolone Br Med J (Clin Res Ed) 286 1983 923 925
25. Monarch Pharmaceuticals Ireland Ltd. Synercid (Quinupristin/Dalfopristin) . UK Summary of product characteristics, March 2005.
26. I. Raad, R. Hachem, and H. Hanna Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction J Antimicrob Chemother 53 2004 1105 1108
27. E. Dodds-Ashley Management of drug and food interactions with azole antifungal agents in transplant recipients Pharmacotherapy 30 2010 842 854
28. A.H. Saad, D.D. DePestel, and P.L. Carver Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants Pharmacotherapy 26 2006 1730 1744
29. Voriconazole. Available at: Http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000387/WC500049756.pdf
30. Posaconazole. Available at: Http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000610/WC500037784.pdf
31. G. Eschenauer, D.D. DePestel, and P.L. Carver Comparison of echinocandin antifungals Ther Clin Risk Manag 3 2007 71 97
32. T. Kuramoto, T. Daikoku, Y. Yoshida, M. Takemoto, K. Oshima, and Y. Eizuru Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir J Pharmacol Exp Ther 333 2010 816 821
33. W.C. Su, W.L. Liu, C.W. Cheng, Y.B. Chou, K.H. Hung, and W.H. Huang Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities FEBS Lett 583 2009 2793 2798
34. Available at: Http://www.hiv-druginteractions.org